Brokerages Set Tandem Diabetes Care, Inc. (NASDAQ:TNDM) PT at $45.38

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has been given a consensus rating of “Moderate Buy” by the eighteen ratings firms that are covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $45.38.

A number of brokerages recently weighed in on TNDM. Morgan Stanley cut Tandem Diabetes Care from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $45.00 to $22.00 in a research note on Wednesday, March 5th. The Goldman Sachs Group dropped their price target on Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating on the stock in a research note on Monday, March 3rd. Robert W. Baird dropped their price target on Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating on the stock in a research note on Thursday, February 27th. Barclays dropped their price target on Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $63.00 price target on shares of Tandem Diabetes Care in a research note on Wednesday, February 26th.

Tandem Diabetes Care Price Performance

NASDAQ:TNDM opened at $20.29 on Monday. The business’s 50-day moving average price is $29.70 and its 200 day moving average price is $33.75. The firm has a market cap of $1.35 billion, a P/E ratio of -10.51 and a beta of 1.45. Tandem Diabetes Care has a 52-week low of $17.64 and a 52-week high of $53.69. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29.

Insider Activity at Tandem Diabetes Care

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos acquired 10,538 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The shares were purchased at an average price of $18.12 per share, with a total value of $190,948.56. Following the completion of the transaction, the chief operating officer now owns 10,538 shares in the company, valued at $190,948.56. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Tandem Diabetes Care

A number of institutional investors have recently modified their holdings of the company. Arizona State Retirement System raised its position in shares of Tandem Diabetes Care by 1.9% in the fourth quarter. Arizona State Retirement System now owns 18,961 shares of the medical device company’s stock valued at $683,000 after purchasing an additional 362 shares during the period. Bank of Montreal Can raised its position in shares of Tandem Diabetes Care by 4.3% in the fourth quarter. Bank of Montreal Can now owns 10,004 shares of the medical device company’s stock valued at $360,000 after purchasing an additional 409 shares during the period. Summit Investment Advisors Inc. raised its position in shares of Tandem Diabetes Care by 8.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,870 shares of the medical device company’s stock valued at $247,000 after purchasing an additional 525 shares during the period. Assetmark Inc. raised its position in shares of Tandem Diabetes Care by 77.5% in the fourth quarter. Assetmark Inc. now owns 1,225 shares of the medical device company’s stock valued at $44,000 after purchasing an additional 535 shares during the period. Finally, AlphaQuest LLC grew its stake in shares of Tandem Diabetes Care by 138.7% in the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company’s stock worth $34,000 after acquiring an additional 541 shares during the last quarter.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.